United Therapeutics CEO trades 9,500 option shares
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share on July 31, 2026, acquiring 9,500 common shares.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share on July 31, 2026, acquiring 9,500 common shares. The trusts then sold 9,500 shares that day in multiple reported transactions at weighted-average prices, all under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust continued to hold 227,410 options, while Rothblatt also held 40,513 shares directly and 166 shares indirectly through her spouse, plus additional holdings in family trusts.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.64M approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.93M)
Approx. gross sale proceeds
$4.93M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.64M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F15 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 365 | $514.8231 | $188K |
| Sale | Common Stock F1, F4, F2 | 857 | $515.8389 | $442K |
| Sale | Common Stock F1, F5, F2 | 1,133 | $516.9427 | $586K |
| Sale | Common Stock F1, F6, F2 | 1,215 | $518.0006 | $629K |
| Sale | Common Stock F1, F7, F2 | 1,266 | $519.0553 | $657K |
| Sale | Common Stock F1, F8, F2 | 2,627 | $520.1182 | $1.37M |
| Sale | Common Stock F1, F9, F2 | 1,517 | $520.8032 | $790K |
| Sale | Common Stock F1, F10, F2 | 282 | $521.5222 | $147K |
| Sale | Common Stock F1, F11, F2 | 238 | $522.8759 | $124K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock F12 | -- | -- | -- |
| Holding | Common Stock F13 | -- | -- | -- |
| Holding | Common Stock F14 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 227,410 contracts (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (15)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $521.49 to $522.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $522.50 to $523.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F13. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F14. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F15. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $514.35 to $515.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $515.40 to $516.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $516.40 to $517.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $517.45 to $518.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $518.46 to $519.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $519.46 to $520.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $520.46 to $521.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 9,500 shares
Common shares sold: 9,500 shares
Representative sale price: $520.1182 per share
+4 more
7 metrics
Options exercised
9,500 shares
Stock options exercised on 2026-07-31 at $135.4200 per share
Common shares sold
9,500 shares
Shares sold on 2026-07-31 in multiple reported transactions by family trusts
Representative sale price
$520.1182 per share
Weighted-average price for 2,627-share sale lot on 2026-07-31
Options remaining in trust
227,410 options
Stock options held indirectly by a family trust after 2026-07-31 exercise
Direct common shares held
40,513 shares
Direct holdings of United Therapeutics common stock as of 2026-07-31
Spouse-held shares
166 shares
Indirect holdings through spouse as of 2026-07-31
Options under trading plan
1,734,410 options
Stock options covered by 10b5-1 plan expiring March 15, 2027, or by December 31, 2026
Key Terms
10b5-1 trading plan, weighted average price, stock options, family trusts
4 terms
10b5-1 trading plan regulatory
"exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"the exercise of 1,734,410 stock options, all of which expire on March 15, 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did UTHR CEO Martine Rothblatt report on July 31, 2026?
Martine Rothblatt reported exercising 9,500 stock options at $135.4200 per share and acquiring 9,500 United Therapeutics common shares, then selling all 9,500 shares in multiple transactions on the same date through family trusts associated with her.
What United Therapeutics options does Martine Rothblatt still hold after this UTHR transaction?
Following the July 31, 2026 option exercise, a family trust associated with Martine Rothblatt still holds 227,410 stock options. Footnotes also reference a 10b5-1 plan that may cover up to 1,734,410 stock options expiring on March 15, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
